Maravai LifeSciences Holdings, Inc. (MRVI)

7,70 -0,02 (-0,32%) A partir del 11:45AM EDT. Mercado abierto.

Maravai LifeSciences Holdings, Inc.

10770 Wateridge Circle
Suite 200
San Diego, CA 92121
United States
858 546 0004
https://www.maravai.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 650

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Carl W. Hull	Co-Founder & Executive Chairman	1,45M	N/A	1959
Mr. William E. Martin III	Chief Executive Officer	2,07M	N/A	1976
Mr. Kevin M. Herde	Executive VP & CFO	778,28k	N/A	1972
Dr. Peter Michael Leddy Ph.D.	Executive VP & Chief Administrative Officer	757k	N/A	1963
Ms. Christine Dolan	Executive Vice President of Biologics Safety Testing	755,97k	N/A	1968
Ms. Debra Hart	Senior Director of Investor Relations	N/A	N/A	N/A
Mr. Kurt Oreshack	Executive VP, General Counsel & Secretary	701,4k	N/A	1981
Ms. Becky Buzzeo	Executive VP & Chief Commercial Officer	N/A	N/A	N/A
Dr. Kate E. Broderick Ph.D.	Chief Innovation Officer	N/A	N/A	N/A
Mr. Christopher Benoit	Executive Vice President of Enzymes	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Maravai LifeSciences Holdings, Inc., a día 1 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 2; Tablero: 10; Derechos de los accionistas: 7; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.